NAS:SGEN (USA) Also Trade In: Brazil Germany

Seagen Inc $ 142.85 -1.62 (-1.12%)

Volume:
496,786
Avg Vol (1m):
1,210,867
Market Cap $:
25.90 Bil
Enterprise Value $:
23.41 Bil
PE Ratio:
43.29
PB Ratio:
7.42
Warning! GuruFocus has detected 2 Severe warning signs with SGEN. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for SGEN (Seagen Inc) from 2001 to Apr 10 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Seagen stock (SGEN) PE ratio as of Apr 10 2021 is 43.29. More Details

Seagen PE Ratio (TTM) Chart

EMBED

Seagen PE Ratio (TTM) Historical Data

Total 1205
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Seagen PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2021-04-1043.3 2021-02-0853.7
2021-04-0943.3 2021-02-0557.8
2021-04-0843.8 2021-02-0450.1
2021-04-0743.8 2021-02-0349.4
2021-04-0644.0 2021-02-0250.3
2021-04-0543.6 2021-02-0149.4
2021-04-0243.5 2021-01-2949.8
2021-04-0143.5 2021-01-2849.3
2021-03-3142.1 2021-01-2749.3
2021-03-3041.7 2021-01-2652.3
2021-03-2942.4 2021-01-2554.6
2021-03-2642.3 2021-01-2255.4
2021-03-2542.2 2021-01-2156.3
2021-03-2442.5 2021-01-2057.8
2021-03-2343.6 2021-01-1957.2
2021-03-2244.9 2021-01-1556.3
2021-03-1944.4 2021-01-1453.3
2021-03-1843.9 2021-01-1353.5
2021-03-1745.4 2021-01-1254.7
2021-03-1644.7 2021-01-1154.3
2021-03-1546.0 2021-01-0853.8
2021-03-1245.7 2021-01-0753.4
2021-03-1146.4 2021-01-0650.5
2021-03-1045.3 2021-01-0551.2
2021-03-0945.6 2021-01-0451.0
2021-03-0845.1 2020-12-3153.1
2021-03-0545.3 2020-12-3055.7
2021-03-0444.1 2020-12-2956.4
2021-03-0344.8 2020-12-2856.3
2021-03-0246.6 2020-12-2475.0
2021-03-0146.2 2020-12-2375.3
2021-02-2645.8 2020-12-2277.5
2021-02-2545.5 2020-12-2177.9
2021-02-2447.0 2020-12-1879.2
2021-02-2347.6 2020-12-1777.9
2021-02-2247.8 2020-12-1677.8
2021-02-1947.8 2020-12-1577.2
2021-02-1848.1 2020-12-1476.2
2021-02-1748.1 2020-12-1175.3
2021-02-1648.3 2020-12-1073.4
2021-02-1550.3 2020-12-0971.4
2021-02-1250.3 2020-12-0872.6
2021-02-1152.1 2020-12-0770.6
2021-02-1051.3 2020-12-0470.6
2021-02-0953.3 2020-12-0370.9

Seagen PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325414 NAICS : 2836
Address
21823 - 30th Drive South East, Building 3, Bothell, WA, USA, 98021
Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.